Loading...
In 2013, AstraZeneca faced a $6 billion problem: the patent on Nexium, its blockbuster acid-reflux drug, was expiring. Rather than invest in novel drug discovery, the company deployed a playbook perfected across the industry. First, it filed 73 patent claims on minor variations—new coatings, different dosage forms, combination formulations—a strategy called 'evergreening' that extended monopoly pricing years beyond the original patent. Nexium itself was already an evergreen: a near-identical molecule to its predecessor Prilosec, repositioned as a 'new' drug when Prilosec's patent expired in 2001. Simultaneously, the pharmaceutical industry spent $350 million annually lobbying Congress—more than any other sector, employing roughly 1,500 lobbyists, nearly three per member of Congress. In ...
Popular framing: Pharma companies are greedy and Congress is bought.
Structural analysis: When the rules of the game can be rewritten by the players, capital flows to lobbying and patent-extension games rather than to discovery. Regulatory capture, pay-for-delay deals, and evergreening produce a stable equilibrium where monopoly rents exceed the cost of preserving them, generating dead-weight loss that no individual firm can unilaterally exit.
The personalization of a structural problem (blaming executives and politicians rather than incentive architectures) systematically misdirects reform energy toward personnel changes that leave the equilibrium intact. Understanding rent-seeking and public choice theory reveals why the same outcomes recur across different firms, different Congresses, and different decades — and why only structural interventions (negotiating authority, patent reform, prize models) can shift the equilibrium rather than merely rotating its beneficiaries.
